The RAS-RAF Pathway panel is a clinical grade, ultra-sensitive liquid biopsy solution for the identification of gene mutations in KRAS, NRAS, BRAF, PIK3CA, and AKT1 to inform therapy selection by detecting established and emerging predictive markers, resistance mutations, and frequently occurring genetic alterations associated with various cancers.
Determine eligibility for anti-EGFR treatment (KRAS/NRAS wild-type), as well as inhibitors of BRAF, PI3K, AKT1, and KRAS. The SafeSEQ Panel enables maximum identification of patients eligible for therapy. Less sensitive technologies can miss a significant subset of patients who may benefit from targeted therapy.
Determine therapeutic efficacy and monitor disease dynamics:
Provides the ability to identify and monitor molecular alterations, including those that may evolve under the influence of treatment exposure. By accurately monitoring disease response and clonal dynamics, The SafeSEQ Panel enables the informed adaptation of therapeutic strategies.
The SafeSEQ RAS-RAF Pathway Panel is CE marked for IVD use and CLIA-validated for use in clinical trials.